TP53 and prostate carcinoma: The in vitro [26-28] and in vivo [29] anti-tumor activities of a novel CDK inhibitor, VMY-1-103 (VMY), were previously described, and VMY induces p53 activity and apoptosis in the wild type p53 prostate cancer cell line, LNCaP [26].